ROCKVILLE, Md.--(BUSINESS WIRE)--SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of diagnostics for neurodegenerative disorders and conditions, including Alzheimer’s Disease (AD), is pleased to announce the creation of an Advisory Council comprised of powerhouse leaders in healthcare innovation: Michael Gorton, founding CEO, Teladoc and CEO, Recuro Health, Wayne Jenkins, MD, MPH, physician executive, Frederick Huie, MD, general surgeon in New York, New York and Dave Rosa, president and CEO, NeuroOne Medical Technologies Corporation.
“These exceptional leaders have been hand-picked for participation on our Advisory Council and reflect the high level of interest and confidence in the capabilities of SDx to introduce a solution that answers the pressing market need among providers, payers and patients for early identification of AD,” says Frank Amato, CEO and president, SDx. “DISCERN™, the first autopsy-validated, highly accurate, minimally invasive test for the definitive diagnosis of AD versus other forms of non-AD dementias and those with AD and other degenerative pathologies, provides payers with a reliable basis for prior authorization and reimbursement of new drugs and therapies to treat AD at the appropriate stage of disease. This Council will work closely with SDx leadership and advise on all matters related to company growth.”
- Michael Gorton, founding CEO, Teladoc, is a 14x serial entrepreneur who has created tens of billions of dollars in net worth from companies he has started. As one of the pioneers of telemedicine and digital health, Gorton helped create what is becoming a trillion dollar industry. The results of his industry-changing efforts can be seen in companies he has founded, such as Internet Global, Teladoc, Palo Duro Records, Back To Space and Principal Solar.
- Wayne Jenkins, MD, MPH is an accomplished physician and executive with a proven track record of patient-centered, revenue-driven results. Over the course of his career, he has consistently transformed large, complex healthcare systems into market leaders that deliver quality and value in a dynamically changing environment.
- Frederick Huie, MD is a general surgeon in New York, New York. He received his medical degree from Georgetown University School of Medicine and has been in practice for more than 20 years.
- Dave Rosa, CEO, NeuroOne Medical Technologies Corporation, is an entrepreneur with three decades of experience in the medical device industry spanning a variety of technologies and products. He has been named as an inventor on multiple medical device patents, serves on four corporate boards and has raised $200 million in the capital markets.
Amato adds, “The unmatched experience of these individuals further strengthens the value, marketability and value of DISCERN as a breakthrough solution, positioning the test as a critical, essential component of patient-centric, value-based strategies. With solid financial support as announced with the closing of our A Round investment and the assignment of Proprietary Laboratory Analyses (PLA-CPT) Codes 206U and 207U, DISCERN is poised to meet significant unmet market need to potentially reduce the economic burden of AD across the healthcare system.”
About SYNAPS Dx
SYNAPS Dx is privately held company focused on the research, development and commercialization of diagnostics for neurological disorders and conditions, including Alzheimer’s Disease. The Company offers DISCERN™, the first accurate, minimally invasive test for the definitive diagnosis of Alzheimer’s disease (AD) versus other forms of dementia. SYNAPS Dx’s laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing. If you are a physician or a patient looking for more information on the DISCERN™ test, visit https://discerntest.com/. For more information on the Company, visit https://www.synapsdx.com/. Contact: info@synapsdx.com.
